The Omicron various offers a new opportunity for IMM
Eftilagimod has been studied with vaccines for both RNA and DNA viruses over 10 years ago.
Safety was not an issue.
A Covid booster study with and without eftilagimod may show increased efficacy of vaccines when used in combination.
Does IMM have enough eftilagimod to provide this for study?
If so Marc and Frederic could announce there are supplies available and free to any big pharma companies willing to do the study.
It might not work but it may confer much better immunity against variants.
Marc Voight, page-13
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |